Stratification of Arrhythmic Risk and/or Heart Failure Risk in Patients With Hereditary Heart Disease

Recruiting now

Conditions studied: Hereditary Heart Diseases

In brief

Sudden cardiac death (SCD) is one of the leading causes of death in developed countries. These deaths (more than 5,000 per year in France) are due to hereditary arrhythmias or cardiomyopathies. Early diagnosis of SCD is often achieved through family screening, but the main challenge is to stratify the risk of SCD in these patients. Indeed, prevention of SCD relies mainly on the implantation of an automatic defibrillator. The challenge is to identify patients who will develop SCD and avoid implanting an implantable cardioverter defibrillator (ICD) in patients who will never develop arrhythmias but who will face complications related to the ICD (inappropriate shocks, infection, lead failure), leading to a reduced quality of life and significant costs for the healthcare system. However, there is a lack of relevant clinical and biological markers for risk stratification, which rules out any possibility of preventive screening. Most of the clinical and ECG (electrocardiogram) parameters identifying an increased risk of SCD have not been reproduced in replication studies. In this project, the investigator will develop a data processing and analysis pipeline using artificial intelligence methods to assess the individual risk of serious arrhythmic events or heart failure in patients with hereditary arrhythmic diseases or cardiomyopathies through the automated processing of multimodal data (clinical data, electrocardiogram (ECG), imaging (echocardiography, MRI magnetic resonance imaging), genetic data, biomarkers).

Key facts

Study ID

NCT07257289

Run by

Nantes University Hospital

People needed

1000

Starts

2026-02-03

Expected to finish

2036-12-12

Last updated by the study team

2026-03-27

Who can join

Age: 1 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• I. hereditary heart disease II. All relatives of patients III. Patients referred to the reference centre for suspected hereditary rhythm disorders or cardiomyopathies IV. Written consent V. social security scheme

You may not qualify if…

• I. Patients participating in a therapeutic trial that may interfere with the research results II. Patients under guardianship or curatorship.

Where it is running

• CHU de Nantes — Nantes, France (enrolling)
• CHU de Brest — Brest, France
• CHU de Clermont-Ferrand — Clermont-Ferrand, France
• CHU de Dijon — Dijon, France
• CHU de La Rochelle — La Rochelle, France
• CHU de Limoges — Limoges, France
• CHU de Montpellier — Montpellier, France
• CHU de Poitiers — Poitiers, France
• CHU de Rennes — Rennes, France
• CHU de Strasbourg — Strasbourg, France
• CHU de Toulouse — Toulouse, France
• CHU de Tours — Tours, France
• CHU de la Martinique — Fort-de-France, Martinique
• CHU de Bordeaux — Bordeaux, France
• CHU de la Réunion — Saint-Pierre, Reunion

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.